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https://doi.org/10.1016/j.ccell.2019.12.014SUMMARYChimeric antigen receptor (CAR) T cell costimulation mediated by CD28 and 4-1BB is essential for CAR-T
cell-induced tumor regression. However, CD28 and 4-1BB differentially modulate kinetics, metabolism
and persistence of CAR-T cells, and the mechanisms governing these differences are not fully understood.
We found that LCK recruited into the synapse of CD28-encoding CAR by co-receptors causes antigen-inde-
pendent CAR-CD3z phosphorylation and increased antigen-dependent T cell activation. In contrast, the syn-
apse formed by 4-1BB-encoding CAR recruits the THEMIS-SHP1 phosphatase complex that attenuates
CAR-CD3z phosphorylation. We further demonstrated that the CAR synapse can be engineered to recruit
either LCK to enhance the kinetics of tumor killing of 4-1BB CAR-T cells or SHP1 to tune down cytokine
release of CD28 CAR-T cells.INTRODUCTION
Chimeric antigen receptors (CARs) are synthetic molecules
composed of a single-chain variable fragment (scFv), costimula-
tory moieties (either CD28 or 4-1BB), and a CD3z signaling
domain that, when expressed by T lymphocytes, trigger their
lytic machinery and costimulation upon antigen engagement
(Dotti et al., 2014; Finney et al., 1998; Gross et al., 1989; Imai
et al., 2004; Sadelain et al., 2013). In clinical studies, CAR costi-
mulation plays an essential role in promoting the expansion of
CAR-redirected T cells, and both CD28 and 4-1BB lead to
equally significant clinical responses in B cell malignancies
(Brentjens et al., 2013; Maude et al., 2014; Savoldo et al.,
2011). However, CD28- and 4-1BB-mediated costimulation in
CAR-T cells has been associated with distinct antitumor kinetics
because the CD28 endodomain promotes faster antitumor activ-Significance
Costimulation mediated by CD28 and 4-1BB endodomains int
tivity. In this study, we have identified that LCK and THEMIS-SH
respectively. Based on these mechanistic findings, we have de
cells to specifically tune their functions.ity compared with the 4-1BB endodomain (Zhao et al., 2015).
This phenomenon correlates with the observed pronounced
glycolytic metabolism and higher susceptibility to exhaustion
of the CD28-mediated costimulation as opposed to the predom-
inantly oxidative metabolism and lower susceptibility to exhaus-
tion of the 4-1BB-mediated costimulation (Kawalekar et al.,
2016; Long et al., 2015).
Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) and
tumor necrosis factor receptor-associated factors (TRAFs)
are known downstream signaling molecules recruited by
CD28 and 4-1BB, respectively (Arch and Thompson, 1998;
Frauwirth et al., 2002). However, PI3K and TRAF signaling
do not explain the observed functional differences between
CD28 and 4-1BB costimulation and it remains elusive
whether key signaling events occur within the CAR synapse
causing the observed kinetics of antitumor activity. Here, weegrated into CAR molecules is critical for their antitumor ac-
P1 complex are differentially recruited by CD28 and 4-1BB,
veloped strategies to engineer either LCK or SHP1 in CAR-T
investigated the molecular mechanisms underlying the func-
tional differences between CD28 and 4-1BB costimulation to
identify strategies for generating CAR-T cells with more predict-
able activity and safer clinical profiles.
RESULTS
CD28 Costimulation Promotes Higher Activation of
CAR-T Cells via LCK-Mediated Constitutive
Phosphorylation of the CAR-CD3z Domain
To stringently compare the CD28 and 4-1BB proximal signaling
in CAR-T cells, we generated two CARs that encode the same
CD19-specific scFv and CD8a stalk, and either the CD28 or
the 4-1BB intracytoplasmic costimulatory domain followed by
the intracytoplasmic tail of the CD3z chain (CAR19.28z and
CAR19.BBz) (Figure S1A). Upon activation, transduction and
expansion of CAR-T cells for 10–14 days after clinically vali-
dated standard operating procedures (Ramos et al., 2016),
the magnitude of CAR19.28z-T and CAR19.BBz-T cell activa-
tion was measured by stimulating them with titrated doses of
an anti-idiotype Ab (a-CAR19 Ab) that crosslinks the CAR (Diac-
onu et al., 2017). CAR19.28z-T cells showed a significantly
higher magnitude of activation than CAR19.BBz-T cells as
measured by Ca2+ influx (Figure 1A) and higher expression of
the early T cell activation marker CD69 in both CD4+ and
CD8+ T cells (Figure 1B). Accordingly, CAR19.28z-T cells
releasedmore interferon g (IFN-g) than CAR19.BBz-T cells (Fig-
ure 1C). In contrast, no significant differences in the expression
of activation markers and cytokine release were observed when
CAR19.28z-T and CAR19.BBz-T cells were stimulated via T cell
receptor (TCR) crosslinking (Figure S1B), indicating that the
costimulation associated with the CAR determines the magni-
tude of activation upon CAR engagement. Similar results were
obtained when CAR19.28z-T and CAR19.BBz-T cells were
simulated via titration of tumor cells expressing the target anti-
gen (Figures 1D and S1C). To confirm our results in vivo,
CAR19.28z-T and CAR19.BBz-T cells were differentially
labeled and infused simultaneously in NSG (NOD-scid IL2Rgnull)
mice bearing CD19+ tumor cells. T cells were then harvested 6 h
after infusion. Tumor cells (CD45+CD3-) and T cells
(CD45+CD3+) were detected in the peripheral blood, bone
marrow, lung, and spleen by flow cytometry (Figure 1E). Gating
on CD45+CD3+ T cells and differentially labeled cells,
CAR19.28z-T cells showed higher expression of CD69 than
CAR19.BBz-T cells in organs that contained less tumor cells,
such as blood, lung, and spleen (Figures 1F and S1D–S1F).
The stronger activation of CAR19.28z-T cells translated into a
more pronounced short-term antitumor activity as compared
with CAR19.BBz-T cells when low doses of CAR-T cells were
used (Figure S1G).
Proximal signalingmolecules are rapidly phosphorylated upon
TCR activation in T cells (Smith-Garvin et al., 2009).We observed
that CAR19.28z-T cells exhibited higher phosphorylation of the
downstream proximal signaling molecules CAR-CD3z, ZAP70,
and LAT when stimulated with the a-CAR19 Ab as compared
with CAR19.BBz-T cells (Figure 1G), and CAR19.28z-T cells
consistently showed higher antigen-independent/basal phos-
phorylation of the CAR-CD3z (Figures 1H and S1H; Table S1).
The latter effect was observed with two other CARs encodingthe CD28 endodomain (Figures S1I and S1J), and regardless
of the type of hinge or transmembrane domain used within the
CAR19 constructs (Figures S1K–S1N). Furthermore, both CD4+
and CD8+ T cells (Figure S1O and S1P) growing with different cy-
tokine(s) (Figures S1Q and S1R) showed higher basal phosphor-
ylation of CAR-CD3z in CAR encoding the CD28 endodomain.
LCK kinase confers more profound phosphorylation events in
CAR19.28z-T cells as compared with CAR19.BBz-T cells (Salter
et al., 2018). We observed that the CAR-CD3z basal phosphory-
lation of CAR19.28z-T cells was abrogated by the addition of Src
family kinase (PP2) or LCK inhibitor (Inh-II) (Awale and Mohan,
2008) (Figure 2A). Furthermore, pretreatment of CAR19-28z-T
cells with PP2, which significantly decreases CAR-CD3z basal
phosphorylation, reduced their responsiveness to CAR cross-
linking with low doses of a-CAR19 Ab to similar levels of
CAR19.BBz-T cells, as shown by the expression of CD69 and
release of IFN-g and interleukin-2 (IL-2) (Figures 2B, C, and
S2A). In contrast, high doses of a-CAR19 Ab partially overcame
the PP2-mediated inhibition in CAR19.28z-T cells (Figures 2B,
2C, and S2B). This suggests that LCK is rapidly recruited in the
CAR19.28z synapse and that a strong CAR aggregation medi-
ated by high doses of a-CAR19 Ab rapidly overcomes the inhib-
itory effects of PP2 pretreatment. Collectively, these data
suggest that higher CAR-CD3z basal phosphorylation primes
CAR19.28z-T cells to a higher magnitude of activity in response
to low antigen stimulation.
Co-receptors Recruits LCK within the CAR Synapse
LCK binds to the PYAPPmotif of CD28 (Dobbins et al., 2016; Ho-
finger and Sticht, 2005; Holdorf et al., 1999). However, we
observed that introduction of loss-of-function mutations to the
PYAPP motif of CAR19.28z (CAR19.28AAAz, CAR19.28YFz, or
CAR19.28AFAAz) (Figures 3A and 3B) did not completely abolish
the association of LCK to CAR19.28z (Figure S3A). Similarly,
basal CAR-CD3z phosphorylation was only modestly reduced
(Figures S3B and S3C), and the cytokine production of
CAR19.28z-T cells remained unaffected (Figure 3C). Since no
significant differences were observed between CD28 mutants
and CAR19.28z in both phosphorylation of the CAR-CD3z and
cytokine production, we chose one representative mutant to
monitor CD69 expression after a-CAR19 activation. There were
no significant differences on CD69 level between CAR19.28z
and CAR19.28AAAzmutation either upon CAR or TCR crosslink-
ing (Figures S3D and S3E). Furthermore, in CAR molecules
pulled down from CAR.19.BBz-T cells we observed the pres-
ence of LCK (Figure 3D) even if the human 4-1BB endodomain
does not contain any known LCK binding motifs (Kim et al.,
1993; Wen et al., 2002). These observations suggest that
LCK is recruited to the CAR synapse by co-receptors rather
than by the CAR-associated CD28 moiety (Rudd et al., 1988;
Veillette et al., 1988). By co-immunoprecipitation-mass spec-
trometry (coIP-MS), we detected unique CD8a peptides span-
ning regions absent in the CAR-CD8a stalk in CARs pulled
down from both CAR19.28z-T and CAR.19.BBz-T cells (Table
S2). Furthermore, overexpression of a CD8a mutant that
cannot bind to LCK (CD8a-SKS, CKCP mutated to SKSP)
(Turner et al., 1990) greatly reduced the basal CAR-CD3z phos-
phorylation in CD4+ T cells expressing the CAR19.28z, while
CD4+ T cells co-expressing CAR.19.BBz and the wild-type
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Figure 1. CAR19.28z-T Cells Show Higher Magnitude of Activation than CAR19.BBz-T Cells after CAR Crosslinking
(A–C) CAR19.28z-T and CAR19.BBz-T cells were stimulated with different concentrations of a-CAR19 Ab and Ca2+ influx (A), CD69 expression in CD4+ and CD8+
T cells (B), and IFN-g release (C) were measured: n = 3 in (A), one-way ANOVA; n = 17 in (B), n = 3 in (C), two-way ANOVA.
(D) CAR19.28z-T and CAR19.BBz-T cells were stimulated with the CD19+ BV173 cell line at different tumor to T cell ratios (T:E). IFN-g levels in the culture su-
pernatants were measured (n = 4, two-way ANOVA).
(E and F) NSG mice engrafted with the CD19+ Daudi cell line were infused with differentially labeled CAR19.28z-T and CAR19.BBz-T cells mixed at a 1:1 ratio.
Samples were collected 6 h after infusion. Non-tumor-bearing NSG mice, infused with mixed CAR19.28z-T and CAR19.BBz-T cells, were used as a negative
control. Representative flow cytometry plots showing T cells (CD45+CD3+) and Daudi tumor cells (CD45+CD3) identified in the peripheral blood, bone marrow,
lung, and spleen (E). Summary of CD69 expression in T cells (n = 5, two-tailed unpaired t test) (F).
(G) Phosphorylation of CAR-CD3z, ZAP70, and LAT in CAR19.28z-T and CAR19.BBz-T cells after stimulation with the a-CAR19 Ab at 10 mg/mL. Cells were
incubated with the a-CAR19 Ab followed by incubation with a goat anti-mouse IgG secondary antibody on ice. CAR-T cells were then transferred to 37C for
indicated time to be activated (n = 3).
(H) CAR-CD3z phosphorylation of CAR19.28z-T and CAR.19.BBz-T cells in the absence of CAR crosslinking. Total CAR detected by the CD3z chain Ab was used
as equal loading. Results of three representative donors are shown. All data are presented as mean ± SEM.
See also Figure S1 and Table S1.CD8a (CD8a-WT) showed increased basal CAR-CD3z phos-
phorylation (Figures 3E and S3F). We did not find any peptide 
of the CD4 co-receptor in the CAR19.28z pull-down product in 
coIP-MS even if CD4+ T cells were still present at days 10–14 
of culture. However, overexpression of the wild-type CD4 in 
both CD4+ and CD8+ CAR19.BBz-T cells increased the basal 
phosphorylation of CAR-CD3z (Figure 3F). As observed for 
TCR signaling (Wiest et al., 1996), our data support the conclu-
sion that LCK recruited to the CAR synapse by either CD8 or 
CD4 co-receptors plays a major role in triggering the basal 
CAR-CD3z phosphorylation.THEMIS-SHP1 Counteracts the Effect of LCK in the CAR
Synapse of CAR-T Cells Encoding 4-1BB
Although co-receptors bring LCK into the CAR19.BBz synapse
(Figures 3D–3F and S3F; Table S2), we observed very low basal
phosphorylation of the CAR-CD3z, suggesting that 4-1BB may
recruit phosphatases to the CAR synapse that counter the
LCK-mediated phosphorylation. Indeed, the tyrosine phospha-
tase inhibitor Na3VO4 promoted antigen-independent phos-
phorylation of CAR-CD3z in CAR19.BBz-T cells (Figure 4A).
Accordingly, coIP-MS demonstrated that THEMIS is more abun-
dantly associated with CAR19.BBz than CAR19.28z (Table S2).
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Figure 2. CAR-CD3z Basal Phosphorylation Causes Higher Magni-
tude of Activation of CAR19.28z-T Cells than CAR19.BBz-T Cells af-
ter CAR Crosslinking
(A) Phosphorylation of CAR-CD3z in CAR19.28z-T and CAR19.BBz-T cells
treated with DMSO (Ctrl), Src family kinase (PP2), or LCK (Inh-II) inhibitors at
10 mM for 16 h. Results of two representative donors are shown.
(B) CD69 expression in CAR19.28z-T and CAR.19.BBz-T cells pretreated with
10 mM PP2 for 16 h and then stimulated with a-CAR19 Ab at various con-
centrations for 6 h. CAR19.28z-T and CAR19.BBz-T cells not exposed to PP2
were used as control. An additional negative control is represented by
CAR19.CD3Y6Fz-T cells, which are T cells expressing the CAR19 in which all
six tyrosine (Y) residues of the three immunoreceptor tyrosine-based activa-
tion motifs of CAR-CD3z were mutated to phenylalanine (F) to completely
abrogate tyrosine phosphorylation of the CAR-CD3z.
(C) CAR19.28z-T and CAR19.BBz-T cells were treated as in (B). Cytokine
release were quantified (n = 3 for cytokine release, n = 5 for CD69 expression,
two-way ANOVA; p value between CAR19.28z-T andCAR19.28z-T cells + PP2
groups).
All data are presented as mean ± SEM. See also Figure S2.Although THEMIS does not have direct phosphatase activity, it
binds to the phosphatase SHP1, and then the THEMIS-SHP1
complex is recruited by LAT to the TCR synapse to regulate
T cell activation (Paster et al., 2015). THEMIS pull-down in
T cells and Jurkat cells co-expressing THEMIS and CARs
confirmed a stronger interaction between THEMIS and
CAR19.BBz than THEMIS and CAR19.28z (Figures S4A and
S4B). Knockdown of THEMIS or SHP1 in CAR19.BBz-T cells us-
ing small hairpin RNA increased their CAR-CD3z basal phos-
phorylation (Figures 4B, 4C, S4C, and S4D), indicating that the
THEMIS-SHP1 complex negatively regulates CAR-CD3z phos-
phorylation of CAR19.BBz. To map the domain of 4-1BB inter-
acting with THEMIS, we generated 4-1BB mutants and foundthat the COOH-terminal deletion of 10 amino acids abolishes
4-1BB interaction with THEMIS (Figure 4D, 4E, and S4E), leading
to increased CAR-CD3z phosphorylation (Figure 4F), Ca2+ influx
(Figures 4G and S4F), CD69 expression, and IFN-g release (Fig-
ures 4H, S4G, and S4H) by the activated CAR19.BBz-T cells.
These data support the conclusion that the THEMIS-SHP1 com-
plex selectively attenuates CAR-CD3z phosphorylation in CAR-T
cells expressing 4-1BB.
Engineering LCK Kinase Fine-Tunes the Antitumor
Activity of CAR-T Cells Encoding 4-1BB
LCK has access to the CAR19.BBz synapse, but its kinase activ-
ity is limited by the presence of the THEMIS-SHP1 complex.
Although the COOH-terminal deletion of 10 amino acids abolish-
ing the 4-1BB interaction with THEMIS promotes the rapid acti-
vation of CAR19.BBz-T cells, this deletion also abrogates the
binding to TRAF2, which would compromise 4-1BB signaling
(Jang et al., 1998). In contrast, LCK overexpression in
CAR19.BBz-T cells may break the balance of kinases and phos-
phatases within the CAR synapse and promote basal CAR-CD3z
phosphorylation (Figure 5A). We found that overexpressed LCK
retains its native N-terminal myristoylation and palmitoylation
(Resh, 1994), and thus accumulates in the cell membrane of
CAR19.BBz-T cells (Figure 5B), increasing the basal phosphory-
lation of CAR-CD3z (Figure 5C) and Ca2+ influx upon antigen
stimulation (Figures 5D and S5A). CAR19.BBz-T cells co-ex-
pressing LCK expanded numerically in vivo in a lymphoma tumor
model (Figure 5E), and showed better control of tumor growth at
a suboptimal cell dose as compared with CAR19.BBz-T cells
(Figures 5F and S5B). Moreover, CAR19.BBz-T cells co-ex-
pressing LCK better controlled tumor growth after tumor re-chal-
lenge as compared with CAR19.28z-T cells (Figure 5F). The
beneficial effect of LCK overexpression in CAR-T cells encoding
4-1BB was also observed in a neuroblastoma model targeting
the GD2 antigen (Figures 5G, 5H, and S5C), without causing
any increase in the expression of PD-1 or TIM3 in CAR-T cells
(Figure 5I). These data support the conclusion that LCK overex-
pression in CAR-T cells expressing 4-1BB promotes faster anti-
tumor activity without compromising their intrinsic enhanced
persistence.
Engineering SHP1 Phosphatase Fine-Tunes the Effector
Function of CAR-T Cells Encoding CD28
CAR-T cells infused in patients with significant leukemia or lym-
phoma tumor burden cause cytokine release syndrome (CRS)
(Lee et al., 2014). While the administration of a monoclonal anti-
body blocking the IL-6 receptor has been demonstrated to be
effective in attenuating the CRS, the implementation of a pre-
cise pharmacologic control of CAR-T cells remains highly
appealing (Diaconu et al., 2017; Foster et al., 2017; Wu et al.,
2015). We modified SHP1 allowing it to be pharmacologically
recruited to the CAR synapse via the FKBP-FRB heterodimeri-
zation process (Figure 6A and S6A). In response to the hetero-
dimerization small molecule AP21967, FKBP-SHP1 forms het-
erodimers with CAR19.28z.FRB, tunes down CAR-CD3z
phosphorylation upon antigen binding (Figure 6B), and reduces
IFN-g release by CAR19.28z-T cells in a reversible manner
without compromising their antitumor activity in vitro (Figures
6C, S6B, and S6C). Similarly, in a xenograft lymphoma model
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Figure 3. Co-receptors Bring LCK into the CAR Synapse
(A) Schema of the CAR19.28z constructs in which specific mutations were included to generate CD28AAA, CD28YF, and CD28AFAA (CD28AAA, mutation of
PYAPP to AYAAA; CD28YF, mutation of PYAPP to PFAPP; CD28AFAA, mutation of PYAPP to AFAAA).
(B) Representative flow plots showing the expression of CAR19 in transduced T cells at day 6 of culture.
(C) Cytokine release of CAR-T cells stimulated with the a-CAR19 Ab at different concentrations for 6 h. Cells were collected at day 14 of culture (n = 3, two-way
ANOVA; n.s., not significant between CAR19.28z-T and CAR19.28AAAz-T, CAR19.28YFz-T, or CAR19.28AFAAz-T cells).
(D) LCK detection by immunoprecipitation (IP) in CAR molecules pulled down from CAR19.28z-T and CAR19.BBz-T cells collected at day 14 of culture.
(E) Phosphorylation of CAR-CD3z Y142 in CD4+ T cells expressing either CAR19.28z or CAR19.BBz and co-transduced with the CD8a mutant (CD8a-SKS) or
wild-type CD8a (CD8a-WT). Results of two representative donors are shown.
(F) CAR-CD3z pY142 phosphorylation in CD4+ or CD8+ CAR19.BBz-T cells overexpressing either CD4 or CD8a.
All data are presented as mean ± SEM. See also Figure S3 and Table S2.
 (Figure 6D), the administration of the AP21967 in vivo reduced 
IFN-g release by CAR19.28z-T cells co-expressing SHP1, 
without impairing their antitumor effects (Figures 6E and  6F).
Because NSG immunodeficient mice are not appropriate 
models for CRS we used a humanized mouse model in which 
CAR-T cell inoculation causes the release of human IL-6 in 
the plasma of the treated mice (Diaconu et al., 2017; Norelli 
et al., 2018). This model reconstitutes high amounts of normal 
human B lymphocytes expressing CD19 that can be targeted 
by CD19-specific CAR-T cells (Diaconu et al., 2017). In these 
humanized mice (Figure 6G), SHP1 recruitment induced by 
the transient administration of AP21967 alleviated their weight 
loss (Figure 6H) and significantly reduced the release in the 
plasma of human IFN-g, IL-6, granulocyte-macrophage col-
ony-stimulating factor, and tumor necrosis factor alpha (Fig-
ures 6I and  S6D). Importantly, the transient use of AP21967
did not impair the therapeutic effect of CAR19.28z-T cells in vivo 
(Figure S6E). The effect of SHP1 heterodimerization in vivo on 
cytokine release was further validated in another CRS model, 
using SCID-beige mice (Giavridis et al., 2018) (Figures S6F 
and S6G). Taken together, these data demonstrate that thetransient recruitment of SHP1 within the CAR19.28z synapse
by the heterodimerization small molecule AP21967 can tune
down the severity of CRS without impairing the antitumor ef-
fects of CAR-T cells.
DISCUSSION
Costimulation plays a fundamental role in promoting the anti-
tumor effects and persistence of CAR-redirected T cells.
Here, we demonstrated that CD28 and 4-1BB endodomains
incorporated into CAR molecules differentially regulate the
equilibrium of phosphorylation and dephosphorylation of the
CAR-CD3z endodomain and this in turn regulates the magni-
tude of CAR-T cell activation. Furthermore, we provide data
supporting the notion that the equilibrium of LCK/THEMIS-
SHP1 can be genetically manipulated to modulated efficacy
and safety of CAR-T cells.
It has been recognized in clinical trials that CD19-specific
CAR-T cells encoding either CD28 or 4-1BB costimulatory
endodomains promote equal antitumor activity in patients
with B cell malignancies (Brentjens et al., 2013; Maude
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Figure 4. THEMIS-SHP1 Complex Attenuates CAR-CD3z Basal Phosphorylation of CAR19.BBz-T Cells
(A) Phosphorylation of CAR-CD3z Y142 in CAR19.28z-T and CAR19.BBz-T cells treated with 200 mMphosphatase inhibitor Na3VO4. NT, non-transduced control.
Results of two representative donors are shown.
(B) THEMIS expression and CAR-CD3z Y142 phosphorylation in CAR19.28z-T and CAR19.BBz-T cells co-transduced with vectors encoding small hairpin RNA
(shRNA) specific for THEMIS and selected by puromycin. Results of two representative donors are shown.
(C) CAR19.28z-T and CAR19.BBz-T cells were co-transduced with vectors encoding shRNA specific for SHP1 and selected by puromycin. CAR-CD3z Y142
phosphorylation and SHP1 were measured by western blot. Results of two representative donors are shown.
(D) Structures of CAR19.BBz and its mutant CAR19.BBz-DC10 (deletion of 10 amino acids at the COOH of 4-1BB).
(E) CAR19.BBz-T or CAR19.BBz-DC10-T cells were co-transduced with a vector encoding FLAG-tagged THEMIS. At day 14 of culture, cells were collected and
THEMIS was immunoprecipitated by FLAG IP. CAR in the IP product was detected by western blot using the a-CD3z Ab.
(F) Phosphorylation of CAR-CD3z Y142 in CAR19.BBz-T and CAR19.BBz-DC10-T cells. Results of two representative donors are shown.
(G) Ca2+ influx in CAR19.28z-T cells, CAR19.BBz-T cells, and CAR19.BBz-DC10-T cells after stimulation with the a-CAR19 Ab. Representative of three donors.
(H) CD69 expression and IFN-g release in CAR19.28z-T cells, CAR19.BBz-T cells, and CAR19.BBz-DC10-T cells upon a-CAR19 Ab stimulation (n = 3 for IFN-g
release, n = 5 for CD69 expression, two-way ANOVA; p value between CAR19.BBz-T cells and CAR19.BBz-DC10-T cells groups). All data are presented as
mean ± SEM. See also Figure S4.et al., 2014). However, preclinical models showed that CD28
and 4-1BB have fundamental biological differences that may
be critical in inducing antitumor effects and in promoting
persistence of CAR-T cells. CD28 costimulation is generally
associated with a very rapid tumor clearance as compared
with 4-1BB, but also more pronounced propensity to exhaus-
tion or less formation of memory T cells as indicated by their
short-term persistence (Long et al., 2015; Zhao et al., 2015).
Here, we mechanistically link the rapid kinetics of CD28 ex-
pressing CAR-T cells with the basal phosphorylation of theCAR-CD3z endodomain. The basal phosphorylation is caused
by LCK recruited within the CAR synapse, which is largely
mediated by co-receptors rather than the CD28 incorporated
within the CAR, and imprints CAR-T cells to higher magnitude
of response immediately upon encountering the antigen. In
sharp contrast, the synapse formed by CAR molecules con-
taining the 4-1BB endodomain selectively recruits the THE-
MIS-SHP1 complex that dephosphorylates the CAR-CD3z en-
dodomain and attenuates T cell activation. We demonstrated
a direct interaction between THEMIS and 4-1BB encoded
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Figure 5. Engineering LCK Kinase in CAR-T Cells Encoding 4-1BB Enhances Their Antitumor Activity In Vitro and In Vivo
(A) Schema illustrating LCK engineering to counter the phosphatase activity of the THEMIS-SHP1 complex in CAR19.BBz-T cells.
(B) Confocal microscopy showing the LCK accumulation in the membrane in CAR19.BBz-T cells co-transduced with the FLAG-tagged LCK. Scale bar, 5 mm. The
experiment was replicated in three donors.
(C) Phosphorylation of the CAR-CD3z Y83 and Y142 in CAR19.28z-T and CAR19.BBz-T cells expressing LCK. Results of two representative donors are shown.
(D) Representative of Ca2+ influx in CAR19.28z-T cells and CAR19.BBz-T cells with or without co-expression of LCK.
(E and F) Quantification of T cells in the peripheral blood (E) and tumor growth monitored by bioluminescence imaging (BLI) (F) in NSG mice engrafted with the
CD19+ Daudi cells and infused with CAR19.28z-T cells or CAR19.BBz-T cells with or without LCK. Re-challenging with Daudi cells was performed at days 25 and
40 after initial CAR-T cell infusion (indicated by arrows) (n = 5, one-way ANOVA).
(G) Tumor growth monitored by BLI in NSG mice engrafted with the neuroblastoma tumor cell line CHLA-255 and infused with either CARGD2.28z-T or
CARGD2.BBz-T cells with or without LCK.
(H and I) T cell number at day 18 (H), and expression of PD-1 and TIM3 at day 22 (I) in circulating CAR-T cells in mice engrafted with the neuroblastoma tumor cells
and treated as described in (G) (n = 3 in NT group, n = 5 in other groups, one-way ANOVA).
All data are presented as mean ± SEM. See also Figure S5.within the CAR by overexpressing a tagged THEMIS, while we 
were not able to show the direct interaction with the endoge-
nous THEMIS. We attribute this weakness to the lack of 
appropriate reagents to immune precipitate the endogenous 
THEMIS. However, all performed experiments highlight the 
biological relevance of the discovered interaction between 
THEMIS and 4-1BB in CAR molecules.
Our mechanistic discoveries have immediate translational 
implications because kinases and phosphatases can be engi-
neered in CAR-T cells to either enhance or tune down their 
activation. We demonstrated that LCK, when overexpressed 
in CAR19.BBz-T cells, breaks the balance of kinases andphosphatases within the CAR synapse increasing the basal
phosphorylation of CAR-CD3z and the speed of their antitumor
effects. However, while CD28 costimulated CAR-T cells are
prone to rapid contraction and possible exhaustion, LCK over-
expression in 4-1BB costimulated CAR-T cells does not affect
the intrinsic property of 4-1BB signaling to promote T cell
persistence since the antitumor response is maintained after
tumor re-challenge. Enhancing the kinetics of antitumor activity
of 4-1BB, while preserving their longevity, may be critical in
controlling rapidly progressive solid tumors.
Toxicities associated with CAR-T cells, such as CRS, remain
of concern (Lichtman and Dotti, 2017). Pharmacologic and
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Figure 6. Engineering SHP1 Phosphatase in CAR-T Cells Encoding CD28 Ameliorates Cytokine Release Syndrome
(A) Schema of the FRB and FKBP domain engineering of SHP1 and CARs to pharmacologically control SHP1 recruitment to the CAR19.28z synapse.
(B) Phosphorylation of CAR-CD3z pY142 in CAR19.28z.FRB-T cells alone or co-transduced with FKBP-SHP1 after the stimulation with a-CAR19 Ab in the
presence of vehicle (ethanol) or 1 mM AP21967. The experiment was replicated in three donors.
(C) IFN-g release in the supernatant by CAR19.28z.FRB-T cells alone or co-transduced with FKBP-SHP1 and incubated with the CD19+ BV173 tumor cell line at a
1:5 ratio in the presence of vehicle or AP21967 (n = 3, values were normalized to average values in vehicle groups, two-way ANOVA; representative of three
donors).
(D) Schema of the NSG mouse model to evaluate the effects of SHP1 heterodimerization in CAR-T cells in vivo. Plasma was collected at days 2 and 3 after T cell
infusion. AP21967 was administrated twice at day 2 every 12 h.
(E) IFN-g level in the plasma of mice illustrated in (D) before (day 2) and after (day 3) the administration of vehicle or AP21967 (n = 9–11, values were normalized to
average values in vehicle groups, two-way ANOVA; pooled data from two independent experiments).
(F) Representative tumor growth monitored by BLI in NSG mice described as in (D) (n = 4–5, representative of two independent experiments).
(G) Schema of the humanized mouse model to evaluate the effects of SHP1 heterodimerization in CAR-T cells in vivo. Plasma was collected at days 1 and 2 after
the infusion of CAR-T cells targeting CD19 and co-expressing SHP1. AP21967 was administrated twice at day 1 every 12 h.
(H and I) Weight change (H), and cytokine detection (I) in humanized mice illustrated in (G) after CAR-T cell infusion. Weight was normalized to the starting weight
before CAR-T cell infusion. Human IFN-g and IL-6 were detected before (day 1) and after (day 2) the administration of vehicle or AP21967 (n = 4, two-way ANOVA).
All data are presented as mean ± SEM. See also Figure S6.remote control of CAR-T cells has been explored to modulate
CAR-T cell expansion in vivo and mitigate side effects (Diaconu
et al., 2017; Foster et al., 2017; Wu et al., 2015). While the remote
control of T cell proliferation remains challenging in the clinical
setting, our mechanistic observation suggests that a temporary
break of T cell activation can be achieved via phosphatase engi-
neering. Phosphatases play a critical role in attenuating CAR
signaling and we demonstrated that SHP1 can be pharmacolog-ically recruited to the CAR synapse and temporarily attenuate
T cell function without eliminating CAR-T cells.
In summary, CD28 and 4-1BB differentially regulate the
equilibrium of phosphorylation and dephosphorylation of
the CAR-CD3z, which in turn regulates the magnitude of
CAR-T cell activation. Engineering kinases and phosphatases
can be used to tune CAR-T cell function for adoptive
immunotherapy.
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Human IL-7 PeproTech Cat# 200-07
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CAR19.28z.FRB.FLAG This manuscript N/A
SFG.THEMIS This manuscript N/A
SFG.LCK This manuscript N/A
SFG.CD8a-SKS This manuscript N/A
SFG.CD8a-WT This manuscript N/A
SFG.CD4 This manuscript N/A
Oligonucleotides
THEMIS shRNA #1: 5’-GAGATCACTGAAGAGCAATAT-3’ UNC shRNA Core Lab TRCN0000128476
THEMIS shRNA #2: 5’-CCCATAGTGACTGAAGTCATA-3’ UNC shRNA Core Lab TRCN0000130264
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Software and Algorithms
Flowjo v10 FlowJo, LLC N/A
GraphPad Prism GraphPad Software Inc. N/A
Living Image v4.5.2 (IVIS imaging) Perkin Elmer N/A
Other
Counting beads Invitrogen Cat# C36950LEAD CONTACT AND MATERIALS AVAILABILITY
Plasmids generated in this study will be made available on request, but we may require a payment and/or a completed Materials 
Transfer Agreement if there is potential for commercial application. Further information and requests for resources and reagents 
should be directed to and will be fulfilled by the Lead Contact, Gianpietro Dotti (gdotti@med.unc.edu).
EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell Lines and Cell Culture
293T cells were cultured in IMDM (Gibco, Invitrogen) supplemented with 10% fetal bovine serum (FBS, HyClone, Thermo Scientific), 
2 mM GlutaMax, 100 I.U./mL penicillin and 100 mg/mL streptomycin (Invitrogen). BV173, Jurkat, Daudi-FFLuc, Raji-FFluc, and CHLA-
255-FFluc cell lines were cultured in RPMI-1640 (Gibco, Invitrogen) supplemented with 10% FBS (HyClone), 2 mM GlutaMax, 100 
I.U./mL Penicillin and 100 mg/mL Streptomycin (Invitrogen). All cell lines were routinely tested for mycoplasma.
Human Samples
For the humanized mouse construction, human fetal liver tissues were obtained from elective or medically indicated termination of 
pregnancy through a non-profit intermediary working with outpatient clinics (Advanced Bioscience Resources, Alameda, CA). The 
use of the tissue in research had no influence on the decision regarding termination of the pregnancy. Informed consent of the 
maternal donor is obtained in all cases, under regulation governing the clinic. We were provided with no information regarding 
the identity of the patients, nor is this information traceable. The project was reviewed by Office of Human Research Ethics at the 
University of North Carolina at Chapel Hill, which has determined that this submission does not constitute human subjects research 
as defined under federal regulations [45 CFR 46.102 (d or f) and 21 CFR 56.102(c)(e)(l)] and does not require IRB approval.
Mouse Studies
Male and female NSG (NOD-scid IL2Rgnull) mice were purchased from the Animal Core Facility at UNC. Female SCID-beige (C.B-
Igh-1b/GbmsTac-Prkdcscid-LystbgN7) mice were purchased from Taconic Biosciences. All the mice were housed in the Animal 
Core Facility at UNC. All mouse experiments were performed in accordance with UNC Animal Husbandry and Institutional Animal 
Care and Use Committee (IACUC) guidelines and were approved by UNC IACUC. For the humanized mouse model to evaluate the 
effects of SHP1 heterodimerization in CAR-T cells in vivo, humanized NSG mice (NSG-hu HSC) were generated as previously re-
ported (Li et al., 2014). Briefly, human fetal liver tissues were obtained from elective or medically indicated termination of preg-
nancy through a non-profit intermediary working with outpatient clinics (Advanced Bioscience Resources). CD34+ hematopoietic 
stem cells (HSC) were transplanted in newborn NSG mice through intra-liver injection of 2 3 105 purified HSC. Human immune cell 
engraftment was detected by flow cytometry 12 weeks after transplantation. This model reconstitutes high amount of normal hu-
man B cells that can be targeted by CD19-specific CAR-T cells, which causes the release of human IL-6 in the plasma of the 
treated mice.
METHOD DETAILS
Plasmids
CD19-specific CARs were constructed using the scFv from the FMC63 monoclonal antibody (Ab) the CD8a stalk including hinge 
and transmembrane domain and CD3z chain intracytoplasmic domain (Diaconu et al., 2017). CAR19.28z and CAR19.BBz 
contained CD28 and 4-1BB endoplasmic domains, respectively. CAR19.28AAAz (mutation of PYAPP to AYAAA), CAR19.28YFz 
(mutation of PYAPP to PFAPP), CAR19.28AFAAz (mutation of PYAPP to AFAAA) and CAR19.BBz-DC10 were generated by over-
lapping PCR. CARGD2 (targeting the GD2 antigen) and CAR138 (targeting the CD138 antigen) were generated by replacing the 
scFv of CAR19. CARs with the IgG1 hinge or the CD28 transmembrane domain were cloned by overlapping PCR to replace 
CD8a hinge or transmembrane domain. CAR19.28.CD3Y6Fz and CAR19.BB.CD3Y6Fz were generated by gene synthesis 
(GeneArt, Thermo Scientific) and cloned into the original CAR19.28z construct. The full-length human THEMIS (GenBank:
NM_001164685.1) and LCK (GenBank: NM_001042771.2) were PCR amplified from a cDNA library of activated T cells, and cloned
into the SFG retroviral vector after the addition of the HA or FLAG tags. Gene expression was verified in both 293T and T cells by
western blot. FRB and FKBP domains were cloned by PCR from plasmid PM-FRB-mRFP-T2A-FKBP-5-ptase (Addgene #40896).
SHP1 full length (GenBank: NM_002831.5) was PCR amplified from a T cell cDNA library, and cloned into the SFG vector with
FKBP. CAR19.28z.FRB.FLAG was generated by overlapping PCR. Lentiviral constructs encoding shRNAs were obtained from
UNC shRNA Core Lab and tested for knockdown efficiency in primary T cells. Two functional shRNAs were selected for functional
assays.
Retrovirus and Lentivirus Production
Retroviral supernatantswere prepared as previously described (Vera et al., 2006). Briefly, 293T cells were transfectedwith 3 plasmids
(retroviral transfer vector, Peg-Pam-e encoding gag-pol, and RDF encoding the RD114 envelope), using GeneJuice transfection
reagent (Novagen). Supernatants were collected at 48 and 72 hr. Lentiviral supernatants were produced in 293T cells with 3 different
plasmids (lentiviral transfer vector, ps.pAX2 for lentiviral gag-pol and pMD.2G for VSV-G envelope). Supernatant was collected at
48 hr for transduction of T cells.
Transduction and Expansion of Human T Cells
Buffy coats from healthy donors were obtained through the Gulf Coast Regional Blood Center, Houston, TX. Peripheral blood mono-
nuclear cells (PBMCs) were isolated with Lymphoprep density separation (Fresenius Kabi Norge) and activated using 1 mg/mL a-CD3
(Miltenyi Biotec) and 1 mg/mL a-CD28 (BD Biosciences) mAb coated plates. Forty eight hr later, T lymphocytes were transduced with
retroviral or lentiviral supernatants using retronectin-coated plates (Takara Bio), and expanded in complete medium (45% RPMI-
1640 and 45% Click’s medium (Irvine Scientific), 10% FBS (Hyclone), 2mM GlutaMAX, 100 I.U./mL of Penicillin and 100 mg/mL of
Streptomycin) with IL-7 (10 ng/mL; PeproTech) and IL-15 (5 ng/mL; PeproTech) or IL-2 (50 U/ml; R&D) (Zhou et al., 2014). Four to
seven days later, cells were collected for in vitro or in vivo experiments. Lentiviral transduced cells were selected in 1 mg/ml puromycin
(Sigma) for 3 - 5 days before T cells were used in functional assays.
Flow Cytometry and Cell Phenotyping
CAR19 expression on T cells was detected with CAR19 a-idiotype antibody followed by a goat a-mouse APC secondary Ab
(BD bioscience) (Diaconu et al., 2017). Murine a-human CD3, CD4, CD8, CD45, CD69 and CD19 Abs were obtained from BD Biosci-
ence. Samples were acquired on a Canto II or Fortessa flow cytometer from BD and data were analyzed using the FlowJo software
(Tree star).
Activation of CD19-Specific CAR-T Cells with the Anti-idiotype Ab or CD19+ Tumor Cells
a-CAR19 and a-CD3 Abs were serially diluted 2-fold, and coated on non-tissue culture treated 96-well plates for 16 hr. Plates were
washed twice before plating T cells (2.5 x 105 cells/well). Plates were centrifuged at 1,000g for 5 min, and incubated at 37C for 6 hr.
Plates were then briefly spun, and 200 ml of the supernatant was collected for ELISA. Cells were collected and stained with a-CAR19,
CD4-PE, CD69-FITC Abs and Zombie Aqua dye (Biolegend) at 4C for 30 min. Samples were fixed and stored for flow cytometry
analysis. For tumor cell-mediated activation, 5 x 104 BV173 tumor cells were seeded in each well of 96-well plates, and T cells were
serially diluted and seeded. Six hr later, supernatant was collected for ELISA.
Cytokine Measurements
Cytokines in culture supernatants and plasma were measured using enzyme-linked immunosorbent assay (ELISA) or magnetic lu-
minex assay following manufacturer’s instructions (R&D Systems). Data were collected and analyzed using the Lumina-200 System
and the Bio-Plex Manager 6.1 software (Bio-Rad).
Ca2+ Influx Assay
T cells were incubated with Ca2+ indicator as per manufacturer’s instructions (Ca2+ influx assay, BD Bioscience). Cells were incu-
bated with a-CAR19 Ab followed by goat a-mouse secondary Ab on ice. Ca2+ current was measured by flow cytometry for time-
lapsed fluorescence change. Cells were first collected on ice as the baseline of the Ca2+ current, and then activated at 37C for
the Ca2+ current during T cell activation.
Immunoprecipitation (IP)
Proteins from T cells were extracted in RIPA lysis buffer (Thermo Scientific) supplemented with 1 x protease/phosphatase Inhibitors
(Thermo Scientific). Equal amount of total proteins was used for IP. Rabbit/mouse IgG (Thermo Scientific) with protein G magnetic
beads (Bio-Rad) was used to pre-clear the lysate and a-CAR19, a-HA or a-FLAGAbswere incubatedwith lysate for 16 hr, and protein
G beads were then used for the pull-down. IP products were dissolved in 2 x SDS Laemmli buffer for Western blot analysis. For mass
spectrometry, >5 x 108 T cells were lysed and a-CAR19 Ab was first crosslinked on protein G beads with Dimethyl pimelimidate
(DMP, Thermo Scientific). 2 x SDS Laemmli buffer without b-mercaptoethanol was used to dissolve the IP product, and b-mercap-
toethanol was supplemented before western blot.
Western Blot
Protein lysate was normalized according to the amount of CAR expression and resolved on 4% - 15% SDS polyacrylamide gel elec-
trophoresis gels (SDS-PAGE, Bio-Rad). After protein transfer onto Polyvinylidene fluoride membranes (Bio-Rad), membranes were 
blocked in 5% non-fat milk in TBS-T and incubated with primary and secondary Abs in TBS-T with 1% milk. The following Abs were 
used: a-CD3pY83 and a-CD3pY142 (Abcam), a-ZAP70pY319, a-ZAP70, a-LATpY191, a-LAT, a-LCK, a-THEMIS, a-SHP1 and a-HA 
tag (Cell Signaling Technology), a-CD3z, a-FKBP, a-b-actin (Santa Cruz), a-FLAG (M2) (Sigma) and horseradish peroxidase conju-
gated secondary Abs (Goat-a-mouse, Goat-a-Rabbit from Thermo Scientific). Membranes were developed with with SuperSignal 
West Femto Maximum Sensitivity Substrate (Thermo Scientific) on a Gel station (Bio-Rad).
Mass Spectrometry
Immunoprecipitated samples (3 biological replicates) were subjected to SDS-PAGE and stained with coomassie. Lanes for each 
sample were excised and the proteins were reduced, alkylated, and in-gel digested with trypsin overnight at 37C. Peptides were 
extracted, desalted with C18 spin columns (Pierce) and dried via vacuum centrifugation. Peptide samples were stored at 80C until 
further analysis. The peptide samples were analyzed by liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS) 
in 3 separated experiments using a Thermo Easy nLC 1000 coupled to a QExactive HF or a Waters nanoAcquity coupled to a Thermo 
LTQ-Orbitrap Velos. Samples were injected onto a PepMap C18 column (75 mm id 3 25 cm, 2 mm particle size) (Thermo Scientific) 
and separated over a 90 or 120 min gradient where mobile phase A was 0.1% formic acid in water and mobile phase B consisted of 
0.1% formic acid in ACN. The LTQ-Orbitrap Velos was operated in data-dependent mode where the 10 most abundant precursors 
were selected for CID fragmentation (35% CE). The QExactive HF was operated in data-dependent mode where the 15 most intense 
precursors were selected for subsequent HCD fragmentation (27 NCE). For the second replicate, a targeted analysis of THEMIS pep-
tides was conducted. The QExactive HF was operated in PRM mode, and an inclusion list was used to target previously identified 
THEMIS peptides. Raw data files were processed using Proteome Discoverer version 2.1 (Thermo Scientific). Peak lists were 
searched against a reviewed Uniprot human database and appended with the CAR-T sequences using Sequest. The following pa-
rameters were used to identify tryptic peptides for protein identification: 10 ppm precursor ion mass tolerance; 0.02 Da product ion 
mass tolerance for QE HF data and 0.6 Da for Velos data; up to two missed trypsin cleavage sites; carbamidomethylation of Cys was 
set as a fixed modification; oxidation of Met, acetylation of N-terminus and phosphorylation of Ser, Thr and Tyr were set as variable 
modifications. The ptmRS node was used to localize the sites of phosphorylation. Peptide false discovery rates (FDR) were calcu-
lated by the Percolator node using a decoy database search and data were filtered using a 5% FDR cutoff.
Xenograft Mouse Models
For long-term in vivo cytotoxicity, male or female NSG (NOD-scid IL2Rgnull) mice were injected intravenously (i.v.) with 2 x 106 CD19+ 
Daudi tumor cell line labeled with the Firefly luciferase gene (Daudi-FFLuc). Four to seven days later, mice received T cells control or 
expressing CARs intravenously (i.v.). For tumor re-challenging experiments, 2 x 106 CD19+ Daudi-FFLuc cells were i.v. injected at 
indicated time point. Tumor growth was monitored every 2 - 3 days by injecting mice intraperitoneally (i.p.) with D-luciferin 
(150 mg/kg, Xenolight, PerkinElmer). Photon emission was analyzed using the Xenogen-IVIS Imaging System as previously validated 
(Diaconu et al., 2017). For short-term in vivo T cell activation, NSG mice were injected with Daudi-FFLuc cells i.v. Two weeks later, 
CAR19.28z-Ts were labeled with Cell-trace Violet (Thermo Scientific) and CAR19.BBz-Ts were labeled with CFSE (Thermo Scientific) 
as per manufacturer’s instructions. Cells were mixed 1:1, and a total 1 x 107 cells were i.v. injected in each mouse. Peripheral blood, 
bone marrow, lung and spleen were harvested 6 hr after T cell injection, dissociated into single cells and stained with a-human CD45-
PE, CD3-APC and CD69-PE-Cy7 Abs. For the neuroblastoma metastatic model, 6 - 8-week-old male or female NSG mice were in-
jected i.v. with CHLA-255-FFluc tumor cell line (2 3 106 cells/mouse). Fourteen days after tumor inoculation, CAR-T cells were 
infused i.v. (Chen et al., 2019). For the NSG mouse model to evaluate the effects of SHP1 heterodimerization in CAR-T cells in vivo, 
mice were injected i.v. with 2 x 106 Daudi-FFLuc cells. Seven days later, 2 x 106 T cells were infused i.v.. AP21967 was administrated 
intraperitoneally twice at 10 mg/kg dose. Tumor growth was monitored twice a week.
Cytokine Release Syndrome Models
Evaluation of CRS in humanized NSG mice was performed as previously described (Diaconu et al., 2017). Mice were infused with 5 x 
106 CAR-T cells at day 0, and plasma was collected at days 1 and 2. AP21967 was administrated intraperitoneally at 10 mg/kg dose 
(Rivera et al., 2012). Weight of each mouse was normalized to starting weight before CAR-T cell infusion. In a second CRS murine 
model, 7 - 10-week-old female SCID-beige (C.B-Igh-1b/GbmsTac-Prkdcscid-LystbgN7, Taconic Biosciences) mice were injected i.p. 
with Raji-FFluc cells (Giavridis et al., 2018). After 21 days, mice were grouped based on the BLI (total flux). Mice were infused i.p. with 
30 x 106 CAR-T cells. Weight of each mouse was normalized to starting weight before CAR-T cell infusion.
Co-culture Assays
CD19+ BV173 tumor cells were seeded into 24-well plates with 5 x 105 cells/well and T cells were added at different effector to target 
(E:T) ratios (E:T=1:1 or 1:5). After 24 hr, supernatant was collected for ELISA. Three days later, cells were collected and stained with 
a-human CD3 and CD19 Abs for flow cytometry analysis.
Immunofluorescence and Confocal Microscopy
Ctrl and CAR19.BBz-T cells with or without FLAG-tagged LCK at day 6 of culture were first stained with CAR19 a-idiotype Ab
followed by the goat anti-mouse IgG conjugated with AlexaFluor 647 (Invitrogen) secondary Ab to detect CAR19 expression. Cells
were then fixed and permeabilized with Cytofix/Cytoperm solution (BD Bioscience) according to manufacturer’s instructions.
Intracellular FLAG-tagged LCK was detected with Rabbit a-FLAG (Cell Signaling Technology) and goat anti-Rabbit IgG conjugated
with AlexaFluor 488 (Invitrogen). Cells were then loaded on slides by Cytospin Cytocentrifuge (Thermo Scientific) and mounted with
ProLong Diamond Antifade Mountant with DAPI (Thermo Scientific). Slides were imaged using confocal microscopy (Zeiss LSM710)
and images were analyzed with Fiji software (ImageJ).
QUANTIFICATION AND STATISTICAL ANALYSIS
Data were presented as mean ± SEM unless indicated otherwise. Statistical analyses were performed using GraphPad Prism
software. Two-tailed unpaired t-test, one-way ANOVA, and two-way ANOVAwere used. Bonferroni’s correction for multiple compar-
isons was used to calculate adjusted p value when appropriate. The exact p values were shown in figures; ns, not significant. Specific
statistical test used for each figure was described in the corresponding figure legend.
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